Online ISSN: 2515-8260

Keywords : Premature Ejaculation

Comparison of Silodosin and Dapoxetine in “on-demand” treatment of Premature ejaculation:A randomized controlled study

Dr. Shiv Shankar Sharma,Dr. Shivam Priyadarshi, Dr. Nachiket Vyas, Dr.S. S. Yadav, Dr. Govind Sharma

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 3, Pages 2819-2823

Aim: To compare Silodosin and Dapoxetine in the “on-demand” treatment of premature ejaculation.
Material and method: The study was conducted in the department of urology and renal transplant S.M.S. Medical College Jaipur from 1st January 2018 to 31st December 2018. We enrolled 90 self-reported casesof PME and excluded the patients below 18 years and above 50 years; patients suffering from orthostatic hypotension, renal impairment, and hepatic impairment. All patients were divided equally into three groups by a simple randomization method using computer-generated random numbers i.e.,Group A(Silodosin 4 mg on-demand), Group B (Dapoxetine 30 mg on-demand), and Group C (placebo on demand). Intravaginal ejaculatory latency time (IELT), premature ejaculation profile (PEP), and the clinical global impression of change for premature ejaculation (CGIC) were recorded in patients, before the initiation of the treatment and after ten coital activities or after one month. Any adverse effects reported by the patients were also recorded.
Results: There was a significant improvement in intravaginal ejaculation latency time in both Silodosin and Dapoxetine groups. Patients of group A and group B reported better scores in all aspects of premature ejaculation profile as compared to placebo. Only three patients reported a reduced amount of ejaculate with silodosin but it was not bothersome to patients.
Conclusion: Silodosin 4 mg may be used safely as a treatment option for PME as its safety profile in LUTS is already well established. It is as effective as Dapoxetine 30 mg with a better side effect profile in the management of premature ejaculation.

Premature Ejaculation: An Updated Overview of Etiology and Diagnosis

Ibrahim Fathi Rashed, Mostafa Kamel Ahmed, Ahmed Mohamed Nabil, Ibrahim Mohammed Ibrahim

European Journal of Molecular & Clinical Medicine, 2021, Volume 8, Issue 3, Pages 4498-4502

Premature ejaculation (PE) is very common disease that affect more than 20% of menand the
most common self-reported male sexual disorder. The two most relevant and evidence-based
definitions of PE are those of International Society for Sexual Medicine (ISSM) and American
Psychiatric Association. Both definitions agree on the chronic aspect of this disorder and the
relatively short time interval between penetration and ejaculation (≤1min), the absence of
voluntary control of ejaculation, and the negative consequences, such as distress in nearly all
vaginal penetrations.